Roche launches new HIV test

BioSpectrum (Asia) - - Supplier News -

Roche has com­mer­cially launched the cobas HIV-1/ HIV-2 test for use on the au­to­mated cobas 6800/8800 Sys­tems in coun­tries that ac­cept CE mark. De­signed to qual­i­ta­tively de­tect and dif­fer­en­ti­ate HIV-1 from HIV-2, the new test is ex­pected to en­able health­care pro­fes­sion­als to pro­vide treat­ment op­tions de­pend­ing on the sub­type in­fec­tions. The in-vitro nu­cleic acid am­pli­fi­ca­tion test is ap­proved for plasma and serum to en­able flex­i­ble PCR test­ing and its dried blood spot (DBS) col­lec­tion card has also been au­tho­rised as a sam­ple type to fa­cil­i­tate test­ing in ru­ral ar­eas. The test also in­cludes a dual tar­get tech­nol­ogy for the de­tec­tion of HIV-1 and can be used to con­firm the in­fec­tion in an in­di­vid­ual with spec­i­mens re­ac­tive for HIV-1 or HIV2 an­ti­bod­ies or anti­gens. The greater sen­si­tiv­ity of PCR tech­nol­ogy of the test is ex­pected to min­imise the pe­riod of de­tec­tion to around one week com­pared to the du­ra­tion of two and four weeks re­quired by ex­ist­ing tests. Based on PCR tech­nol­ogy, the fully in­te­grated and au­to­mated cobas 6800 and cobas 8800 sys­tems are de­signed for molec­u­lar test­ing in vi­ral load mon­i­tor­ing, donor screen­ing, women’s health, and mi­cro­bi­ol­ogy.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.